Smoking Cessation Treatment for Methadone Maintenance Patients

• Status: Completed
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients in substance abuse treatment smoke four times more than non-substance abusers, and suffer high rates of tobacco-related disease and death. While many quit smoking treatments exist that have been shown to help non-substance abusers quit smoking, little is known about what treatments work for patients in substance abuse treatment. The drug varenicline (Chantix) has been shown to be more effective at helping people quit smoking than nicotine replacement therapy, bupropion or placebo. However, varenicline has not yet been studied in patients in substance abuse treatment. The study aims to evaluate the feasibility, effectiveness and safety of varenicline, in combination with counseling, in methadone maintained smokers. It also aims to evaluate the link between quitting smoking and alcohol and illicit drug use in methadone maintained smokers. We hypothesize that participants receiving varenicline will have higher abstinence from smoking than participants receiving placebo and that participants taking varenicline will not have significantly more adverse reactions than were described in the general population in other studies. We also hypothesize that compared to continued smokers, tobacco abstainers will be more likely to be abstinent from alcohol or illicit drugs.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Albert Einstein College of Medicine; Albert Einstein College of Medicine of Yeshiva University
• Collaborator: National Center for Research Resources (NCRR)
• Treatments: Methadone; Varenicline

Criteria

Inclusion Criteria:

• Age 18 or older

• English speaking

• Smoked at least 100 cigarettes/lifetime

• Smokes 5 or more cigarettes per day

• Interested in quitting smoking (preparation or contemplation state of change)

• Enrolled in Einstein/Montefiore methadone program for 3 or more months

• Stable methadone dose for 2 weeks

• Agree to use contraception throughout the trial (among women with reproductive potential)

• Willing to participate in all study components

• Able to provide informed consent

Exclusion Criteria:

• Serious or unstable HIV/AIDS, liver, cardiovascular, or pulmonary disease

• Psychiatric instability

• Women who are pregnant, breastfeeding, or contemplating pregnancy

• Creatinine clearance less than 30 mL/min